In a report released yesterday, Ken Cacciatore from Cowen & Co. maintained a Buy rating on Foamix Pharma (FOMX), with a price target of $30. The company’s shares closed yesterday at $4.59, close to its 52-week low of $4.12.
According to TipRanks.com, Cacciatore is a 3-star analyst with an average return of 2.6% and a 46.2% success rate. Cacciatore covers the Healthcare sector, focusing on stocks such as Liquidia Technologies Inc, Alder Biopharmaceuticals, and Adamas Pharmaceuticals.
Currently, the analyst consensus on Foamix Pharma is a Strong Buy with an average price target of $18.67, which is a 306.8% upside from current levels. In a report released yesterday, Cantor Fitzgerald also assigned a Buy rating to the stock with a $15 price target.
.
See today’s analyst top recommended stocks >>
Based on Foamix Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $18.63 million. In comparison, last year the company had a GAAP net loss of $17.58 million.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Foamix Pharmaceuticals Ltd. is a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel.
